Smithkline Beecham Corporation

Glaxosmithkline Intellectual Property (no.2) Limited

Brad Richard Henke

Rodolfo Cadilla

Millard Hurst Lambert, Iii

Philip Stewart Turnbull

Amy Tsai Lu

David Harold Drewry

Paul Kenneth Spearing

Frank Preugschat

Curt Haffner

J David Becherer

Christie Schulte

Guangcheng Kevin Liu

David Norman Deaton

Jennifer Susan Smith

Ronnie Lee Hale

Compounds of Formula I and methods of treating diseases of metabolism by modulating cellular NAD+ levels through the inhibition of the CD38 enzyme, are disclosed. 

CD38 inhibitors and methods of treatment

Compounds of formula (1) or a pharmaceutically acceptable salt, solvate, acid isostere, or hydrolyzable ester thereof, are disclosed. Methods of making and using the compounds are also disclosed. In particular methods for treating diseases or conditions associated with one or more of human PPAR alpha, gamma, or delta ('hPPARs') comprising administration of a therapeutically effective amount of a compound of formula (1), are disclosed 

hPPARs activators

Aminopyridine derivatives of the following formula I which exhibit pharmacological activity at estrogen receptors alpha (ER&#x3b1;) and beta (ER&#x3b2;) are described herein. The described invention also includes compositions and medicaments containing the aminopyridine derivatives as well as processes for the preparation and use of such compounds, compositions and medicaments.

Aminopyridine derivatives as estrogen receptor modulators

Triazine derivatives of formula (I), which exhibit pharmacological activity at estrogen receptors alpha (ER alpha) and beta (ER beta) are described herein. The described invention also includes compositions and medicaments containing the triazine derivatives as well as processes for the preparation and use of such compounds, compositions and medicaments.

Piperazinyltriazines as estrogen receptor modulators

Growing community of inventors

Durham, NC, United States of America

Brad Richard Henke